此次股份购买后，杨博士持有合共相当于公司于公告日期的已发行股本总额约4.87%的股份。杨博士表 示，其对公司长期投资价值和核心竞争优势充满信心，增持公司股份亦代表其相信公司有能力在未来保 持稳健经营和高品质增长。杨博士并不排除可能适时进一步增持公司股份。 消息面上，1月27日，基石药业发布公告称，公司已获公司首席执行官、研发总裁兼执行董事杨建新博 士告知，其于2025年11月至2026年1月以个人资金在公开市场上合共购买97.6万股股份，其中仅2026年1 月22日及1月23日共购买42.85万股股份。此次近期购买延续了杨博士一贯的坚定承诺。自2022年8月担 任首席执行官以来，杨博士累计购买合共1247.7万股股份。 智通财经APP获悉，基石药业-B(02616)涨超4%，截至发稿，涨4.24%，报5.66港元，成交额1493.18万港 元。 ...

Core Viewpoint - The announcement details a voluntary share purchase plan by certain directors, supervisors, and senior management of Suzhou Bank, reflecting their confidence in the company's future development and long-term investment value [2][5]. Group 1: Share Purchase Plan - The plan involves a total purchase of at least 4.2 million RMB worth of shares from September 8, 2025, to December 31, 2025, through the Shenzhen Stock Exchange [2][5]. - The participating individuals include key executives such as the chairman, vice presidents, and other senior management [2][3]. Group 2: Current Shareholding - As of the announcement, the total shares held by the participating individuals amount to 2,336,280 shares, representing 0.0523% of the company's total shares [3]. - Notable individual holdings include: - Chairman Cui Qingjun: 100,000 shares (0.0022%) - President Wang Qiang: 205,300 shares (0.0046%) - Risk Director Hou Bin: 707,800 shares (0.0158%) [3]. Group 3: Previous Share Purchase Plans - A previous share purchase plan was announced on November 16, 2024, with a target of at least 3.6 million RMB, which was successfully completed with a total purchase of 464.03 million RMB, exceeding the minimum target by 128.90% [5][6]. - The previous plan also involved similar key executives and was executed under the same trading regulations [5].